After a Landmark Supreme Court Ruling, Bayer’s Stock Has Nearly Doubled. The Hard Part Is Next.
30.06.2026 - 19:12:22 | boerse-global.de
Bayer shares stormed to a fresh 2026 high on the final trading day of the first half, adding 5.02% to close at €48.16. The catalyst was a seismic legal victory six days earlier: on June 25, the US Supreme Court ruled 7–2 that federal approval of the herbicide glyphosate overrides stricter warning requirements imposed by individual states. The decision vaporises the legal foundation of tens of thousands of failure-to-warn lawsuits that had dogged the German conglomerate for years.
Over the past seven days alone, the stock has surged roughly 19%. Since plumbing a 52-week low of €25.09 last August, Bayer’s market value has effectively doubled. Yet the rally is already flashing cautionary signals. The Relative Strength Index has climbed to 76.2, firmly into overbought territory, and the annualised volatility of the shares stands at an extraordinary 58%.
The Supreme Court’s decision centres on pre-emption: the Environmental Protection Agency’s approval of glyphosate as safe means US states cannot impose their own cancer-warning labels. That shuts down the majority of outstanding Roundup claims at a stroke. To tidy up the remaining exposure, Bayer has now placed a $7.25 billion settlement offer on the table. That would come on top of more than $10 billion already paid to claimants globally. The question now is whether plaintiffs’ lawyers will accept the terms, with the next court hearing looming in early July.
Should investors sell immediately? Or is it worth buying Bayer?
Beyond the courtroom, Bayer’s operational story has quietly improved. First-quarter earnings beat expectations, and the pharma pipeline is beginning to deliver. European and US regulators are reviewing the stroke-prevention drug Asundexian after a Phase III trial showed a 26% reduction in stroke risk compared with placebo. If approved, the drug could provide a badly needed revenue stream to offset the cash drain of legal settlements.
Still, the balance sheet remains heavily leveraged. Net financial debt runs into the billions, and the proposed settlement – assuming it gains approval – will deepen that hole. The rally has lifted the stock well above its 200-day moving average of €36.68, but technical analysts note that such rapid moves often invite a pullback.
Political and scientific headwinds also persist. The International Agency for Research on Cancer continues to classify glyphosate as “probably carcinogenic”, keeping the public debate alive even as the courts rule in Bayer’s favour. Any new state-level legislative initiatives could reopen old wounds.
For now, the market is betting that the Supreme Court victory marks a definitive turning point. The near-term focus rests on the July hearing, where a Missouri judge will decide whether to approve the $7.25 billion settlement. If the deal goes through, Bayer can finally begin to shift investor attention from litigation risk to the commercial potential of its pipeline. If it stalls, the stock’s heady gains may prove as fragile as the legal settlement it is built on.
Ad
Bayer Stock: New Analysis - 30 June
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
